Regeneron Presents P-I/II (CHORD) Trial Data of DB-OTO for Profound Genetic Hearing Loss at Association for Research in Otolaryngology 2025
Shots:
- Ongoing P-I/II (CHORD) trial assessed DB-OTO (intracochlear) in 12 pts (10mos.-16yrs.) with hearing loss due to variation in OTOF gene, where 9 pts received it in 1 ear, while 3 received it in both; pts enrolment (<18yrs.) ongoing in the US, UK & Spain
- At 48 wks., first subject (10mos. old) showed improved hearing to near-normal levels (0.25–2.0 kHz) & depicted positive ABRs. Speech perception was also improved, with correct word recognition at 48–72wks.
- 10/11 pts showed improved hearing at various dBHL in ≥1 post-therapy test. At 24wks., 3/5 pts improved to nearly normal (n=1, ≤40 dBHL) or normal (n=2, ≤25 dBHL) hearing levels with ABR aligning to PTA data, while 1/5 showed no change
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron Reports US FDA’s Acceptance of Resubmitted BLA for Linvoseltamab to Treat R/R Multiple Myeloma (MM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
